News headlines about CryoLife (NYSE:CRY) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. CryoLife earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 46.4448953509313 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news articles that may have effected Accern’s analysis:

A number of research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of CryoLife from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. BidaskClub downgraded shares of CryoLife from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. CryoLife has a consensus rating of “Hold” and a consensus price target of $22.00.

CryoLife (NYSE CRY) opened at 22.70 on Friday. The firm has a 50 day moving average of $20.14 and a 200-day moving average of $18.49. CryoLife has a 12 month low of $14.03 and a 12 month high of $23.35. The firm has a market cap of $759.22 million, a P/E ratio of 68.79 and a beta of 0.97.

CryoLife (NYSE:CRY) last issued its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.10 by $0.02. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. The company had revenue of $47.80 million for the quarter, compared to the consensus estimate of $47.02 million. During the same period last year, the firm posted $0.13 EPS. CryoLife’s revenue for the quarter was up 1.5% on a year-over-year basis. On average, equities research analysts forecast that CryoLife will post $0.43 earnings per share for the current year.

In other news, CEO James P. Mackin sold 43,050 shares of the firm’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $22.09, for a total value of $950,974.50. Following the completion of the sale, the chief executive officer now owns 398,399 shares in the company, valued at approximately $8,800,633.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO James P. Mackin sold 125,000 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $22.01, for a total transaction of $2,751,250.00. Following the completion of the sale, the chief executive officer now owns 398,399 shares of the company’s stock, valued at approximately $8,768,761.99. The disclosure for this sale can be found here. Insiders have sold a total of 169,050 shares of company stock worth $3,724,225 over the last three months. 6.00% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect CryoLife (CRY) Share Price” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-cryolife-cry-share-price/1598527.html.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Insider Buying and Selling by Quarter for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.